Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

This study is testing four different dosing schedules of a drug called OTL78 — a fluorescent dye that attaches to prostate cancer cells and lights them up during surgery — to find the best dose for helping surgeons identify and remove prostate cancer tissue more accurately. **You may be eligible if...** - You are male and 18 years of age or older - You have confirmed prostate cancer that is high-grade (Grade Group 3 to 5) - Your cancer shows signs of spreading beyond the prostate capsule (extracapsular extension), into seminal vesicles, or involves multiple high-grade biopsy cores - You are scheduled for prostate surgery **You may NOT be eligible if...** - You have low or intermediate-grade prostate cancer (Grade Group 1 or 2) without high-risk features - You have kidney problems that would prevent safe use of this dye - You have a known allergy to related compounds - You are not scheduled for surgery Talk to your doctor to see if this trial is right for you.